Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 10Gastrointestinal 8Breast 8Thoracic 7Head & Neck 5Genitourinary 5Sarcoma 3Other hematologic neoplasm 2Dermatologic 2Plasma cell 1Lymphoid 1CNS 1

Conditions

Sarcoma 6Breast Neoplasms 5Ovarian Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Pathologic Complete Response 1Neoplasm Metastasis 1Lung Neoplasms 1Hemangiosarcoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1

Interventions

Filgrastim 14Cyclophosphamide 13Carboplatin 12Paclitaxel 8Ifosfamide 8Doxorubicin 8pembrolizumab 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6fludarabine 5Temozolomide 5Specimen Handling 5Radiotherapy 5Cisplatin 5Magnetic Resonance Spectroscopy 4Etoposide 4Docetaxel 4Amifostine 4aldesleukin 3Trastuzumab 3Taxes 3Psychiatric Rehabilitation 3Melphalan 3Fulvestrant 3Bevacizumab 3sodium thiosulfate 2pazopanib 2pamiparib 2palbociclib 2etoposide phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Trastuzumab × Sarcoma × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Jonsson Comprehensive Cancer Center

Phase NA Completed
12 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡